These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 31578734

  • 1. Diagnostic utility of pan-Trk immunohistochemistry for inflammatory myofibroblastic tumours.
    Yamamoto H, Nozaki Y, Kohashi K, Kinoshita I, Oda Y.
    Histopathology; 2020 Apr; 76(5):774-778. PubMed ID: 31578734
    [Abstract] [Full Text] [Related]

  • 2. Pan-tropomyosin receptor kinase immunoreactivity, ETV6-NTRK3 fusion subtypes, and RET rearrangement in salivary secretory carcinoma.
    Yamamoto H, Nozaki Y, Sugii A, Taguchi K, Hongo T, Jiromaru R, Sato M, Nakano T, Hashimoto K, Fujiwara M, Oda Y.
    Hum Pathol; 2021 Mar; 109():37-44. PubMed ID: 33301751
    [Abstract] [Full Text] [Related]

  • 3. Pan-TRK Immunohistochemistry Is Highly Correlated With NTRK3 Gene Rearrangements in Salivary Gland Tumors.
    Csanyi-Bastien M, Lanic MD, Beaussire L, Ferric S, François A, Meseure D, Jardin F, Wassef M, Ruminy P, Laé M.
    Am J Surg Pathol; 2021 Nov 01; 45(11):1487-1498. PubMed ID: 33899788
    [Abstract] [Full Text] [Related]

  • 4. Primary inflammatory myofibroblastic tumour of the liver: a clinicopathological and genetic study including a subset with ETV6::NTRK3 fusion.
    Han Q, Zhang Z, He X, Chen M, Pang X, Chen C, Du T, Zhang H.
    Histopathology; 2023 May 01; 82(6):925-936. PubMed ID: 36748182
    [Abstract] [Full Text] [Related]

  • 5. ALK, ROS1 and NTRK3 gene rearrangements in inflammatory myofibroblastic tumours.
    Yamamoto H, Yoshida A, Taguchi K, Kohashi K, Hatanaka Y, Yamashita A, Mori D, Oda Y.
    Histopathology; 2016 Jul 01; 69(1):72-83. PubMed ID: 26647767
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of pan-TRK immunohistochemistry in infantile fibrosarcoma, lipofibromatosis-like neural tumour and histological mimics.
    Hung YP, Fletcher CDM, Hornick JL.
    Histopathology; 2018 Oct 01; 73(4):634-644. PubMed ID: 29863809
    [Abstract] [Full Text] [Related]

  • 7. Immunohistochemistry with a pan-TRK antibody distinguishes secretory carcinoma of the salivary gland from acinic cell carcinoma.
    Hung YP, Jo VY, Hornick JL.
    Histopathology; 2019 Jul 01; 75(1):54-62. PubMed ID: 30801752
    [Abstract] [Full Text] [Related]

  • 8. Expression of ROS1 predicts ROS1 gene rearrangement in inflammatory myofibroblastic tumors.
    Hornick JL, Sholl LM, Dal Cin P, Childress MA, Lovly CM.
    Mod Pathol; 2015 May 01; 28(5):732-9. PubMed ID: 25612511
    [Abstract] [Full Text] [Related]

  • 9. Epithelioid inflammatory myofibroblastic sarcoma: An aggressive intra-abdominal variant of inflammatory myofibroblastic tumor with nuclear membrane or perinuclear ALK.
    Mariño-Enríquez A, Wang WL, Roy A, Lopez-Terrada D, Lazar AJ, Fletcher CD, Coffin CM, Hornick JL.
    Am J Surg Pathol; 2011 Jan 01; 35(1):135-44. PubMed ID: 21164297
    [Abstract] [Full Text] [Related]

  • 10. ETV6-NTRK3 Is Expressed in a Subset of ALK-Negative Inflammatory Myofibroblastic Tumors.
    Alassiri AH, Ali RH, Shen Y, Lum A, Strahlendorf C, Deyell R, Rassekh R, Sorensen PH, Laskin J, Marra M, Yip S, Lee CH, Ng TL.
    Am J Surg Pathol; 2016 Aug 01; 40(8):1051-61. PubMed ID: 27259007
    [Abstract] [Full Text] [Related]

  • 11. Using pan-TRK and RET Immunohistochemistry for the Detection of Fusion Types of Salivary Gland Secretory Carcinoma.
    Su YJ, Lee YH, Jin YT, Hsieh MS.
    Appl Immunohistochem Mol Morphol; 2022 Apr 01; 30(4):264-272. PubMed ID: 35384876
    [Abstract] [Full Text] [Related]

  • 12. Clinicopathological features and immunohistochemical utility of NTRK-, ALK-, and ROS1-rearranged papillary thyroid carcinomas and anaplastic thyroid carcinomas.
    Nozaki Y, Yamamoto H, Iwasaki T, Sato M, Jiromaru R, Hongo T, Yasumatsu R, Oda Y.
    Hum Pathol; 2020 Dec 01; 106():82-92. PubMed ID: 32980422
    [Abstract] [Full Text] [Related]

  • 13. Expanding the Molecular Characterization of Thoracic Inflammatory Myofibroblastic Tumors beyond ALK Gene Rearrangements.
    Chang JC, Zhang L, Drilon AE, Chi P, Alaggio R, Borsu L, Benayed R, Travis WD, Ladanyi M, Antonescu CR.
    J Thorac Oncol; 2019 May 01; 14(5):825-834. PubMed ID: 30550870
    [Abstract] [Full Text] [Related]

  • 14. Molecular characterization of inflammatory myofibroblastic tumors with frequent ALK and ROS1 gene fusions and rare novel RET rearrangement.
    Antonescu CR, Suurmeijer AJ, Zhang L, Sung YS, Jungbluth AA, Travis WD, Al-Ahmadie H, Fletcher CD, Alaggio R.
    Am J Surg Pathol; 2015 Jul 01; 39(7):957-67. PubMed ID: 25723109
    [Abstract] [Full Text] [Related]

  • 15. Pan-Trk immunohistochemistry is a sensitive and specific ancillary tool for diagnosing secretory carcinoma of the salivary gland and detecting ETV6-NTRK3 fusion.
    Xu B, Haroon Al Rasheed MR, Antonescu CR, Alex D, Frosina D, Ghossein R, Jungbluth AA, Katabi N.
    Histopathology; 2020 Feb 01; 76(3):375-382. PubMed ID: 31448442
    [Abstract] [Full Text] [Related]

  • 16. Pan-TRK Immunohistochemistry: A Useful Diagnostic Adjunct For Secretory Carcinoma of the Breast.
    Harrison BT, Fowler E, Krings G, Chen YY, Bean GR, Vincent-Salomon A, Fuhrmann L, Barnick SE, Chen B, Hosfield EM, Hornick JL, Schnitt SJ.
    Am J Surg Pathol; 2019 Dec 01; 43(12):1693-1700. PubMed ID: 31498178
    [Abstract] [Full Text] [Related]

  • 17. Detection of NTRK fusions in glioblastoma: fluorescent in situ hybridisation is more useful than pan-TRK immunohistochemistry as a screening tool prior to RNA sequencing.
    Bourhis A, Caumont C, Quintin-Roué I, Magro E, Dissaux G, Remoué A, Le Noac'h P, Douet-Guilbert N, Seizeur R, Tyulyandina A, Schick U, Merlio JP, Marcorelles P, Cappellen D, Uguen A.
    Pathology; 2022 Feb 01; 54(1):55-62. PubMed ID: 34518039
    [Abstract] [Full Text] [Related]

  • 18. Spectrum of kinase gene rearrangements in a large series of paediatric inflammatory myofibroblastic tumours.
    Preobrazhenskaya EV, Suleymanova AM, Bizin IV, Zagrebin FA, Romanko AA, Saitova ES, Mulkidzhan RS, Imyanitov EN.
    Histopathology; 2023 Jul 01; 83(1):109-115. PubMed ID: 37071060
    [Abstract] [Full Text] [Related]

  • 19. Abdominal inflammatory myofibroblastic tumour: Clinicopathological and molecular analysis of 20 cases, highlighting potential therapeutic targets.
    Vernemmen AIP, Samarska IV, Speel EM, Riedl RG, Goudkade D, de Bruïne AP, Wouda S, van Marion AM, Verlinden IV, van Lijnschoten I, Friederich P, Winnepenninckx VJL, Zur Hausen A, Sciot RME, van den Hout MFCM.
    Histopathology; 2024 Apr 01; 84(5):794-809. PubMed ID: 38155480
    [Abstract] [Full Text] [Related]

  • 20. Uterine Inflammatory Myofibroblastic Neoplasms With Aggressive Behavior, Including an Epithelioid Inflammatory Myofibroblastic Sarcoma: A Clinicopathologic Study of 9 Cases.
    Collins K, Ramalingam P, Euscher ED, Reques Llanos A, García A, Malpica A.
    Am J Surg Pathol; 2022 Jan 01; 46(1):105-117. PubMed ID: 34138797
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.